Takeda Pharmaceutical Company Limited / Fundamentals
Income statement
- Net revenue
€25.88B - Cost of goods sold
€11.03B - Gross profit
€14.85B - SG&A expenses
€6.30B - R&D expenses
€4.08B - EBITDA
€7.00B - D&A
€4.34B - EBIT
€2.34B - Interest expenses
€1.49B - EBT
€1.10B - Tax expenses
€300.32M - Net income
€790.96M
Cash flow statement
- Net deferred tax
€324.59M - Non-cash items
€70.24M - Changes in working capital
€341.85M - Operating cash flow
€5.88B - Capex
€1.26B - Other investing cash flow
-€319.43M - Net investing cash flow
-€1.46B - Total cash dividends paid
-€1.79B - Issuance of common stock
€0.00 - Debt repayment
-€3.89B - Other financing cash flow
-€786.48M - Net financing cash flow
-€7.05B - Foreign exchange effects
-€123.27M - Net change in cash
-€1.99B - Cash at end of period
€2.02B - Free cash flow
€7.15B
Balance sheet
- Cash and cash equivalents
€2.02B - Cash and short-term investments
€2.42B - Total receivables
€3.93B - Inventory
€7.17B - Other current assets
€1.00B - Total current assets
€14.52B - Property, plant & equipment
€11.30B - Goodwill
€30.59B - Intangible assets
€19.77B - Long-term investments
€2.01B - Other non-current assets
€396.02M - Total non-current assets
€66.38B - Total assets
€80.90B - Accounts payable
€2.43B - Short-term debt
€2.14B - Other current liabilities
€7.08B - Total current liabilities
€12.53B - Long-term debt
€23.89B - Deferred tax liabilities
€193.60M - Other non-current liabilities
€4.62B - Total non-current liabilities
€28.70B - Total liabilities
€41.24B - Common stock
€9.79B - Retained earnings
€6.68B - Other equity
€13.56B - Total equity
€39.66B - Total liabilities and shareholders' equity
€80.90B
Company information
- Market capitalization
€40.54B - Employees
49K - Enterprise Value
€11.01T
Company ratios
- Gross margin
-
57.4% Worse than peer group: 74.8% - EBITDA margin
-
27.0% Even with peer group: 22.1% - EBIT margin
-
9.0% Worse than peer group: 21.8% - EBT margin
-
4.2% Worse than peer group: 18.6% - Net margin
-
3.1% Worse than peer group: 13.5% - ROE
-
2.0% Worse than peer group: 8.4% - ROA
-
1.0% Even with peer group: 3.9% - Asset turnover
-
32.0% Worse than peer group: 37.8% - FCF margin
-
17.9% Better than peer group: 4.8% - FCF yield
11.4% - Efficiency ratio
73.0% - Net sales per employee
-
€525.17K - Net income per employee
-
€16.05K